Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival
Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response
FDA Grants Accelerated Approval to Imbruvica
Two Papers Evaluate CyberKnife Survival Rates and Tolerability
ANG1005 Demonstrates Activity In Patients with Brain Metastases
MM-121 Study Fails PFS Endpoint, Biomarker Analysis Continues
AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial
NCI CTEP Approved Trials For the Month of November
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- No need for a speculum? A new era of HPV screening
- At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.” - Forty years after Chernobyl: Little evidence to show that radiation released from the accident increased cancers globally
